ZA201800787B - Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy - Google Patents

Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Info

Publication number
ZA201800787B
ZA201800787B ZA2018/00787A ZA201800787A ZA201800787B ZA 201800787 B ZA201800787 B ZA 201800787B ZA 2018/00787 A ZA2018/00787 A ZA 2018/00787A ZA 201800787 A ZA201800787 A ZA 201800787A ZA 201800787 B ZA201800787 B ZA 201800787B
Authority
ZA
South Africa
Prior art keywords
ido1
tdo
oxide
dioxygenases
tryptophan
Prior art date
Application number
ZA2018/00787A
Other languages
English (en)
Inventor
Brian Desmond Palmer
Lai-Ming Ching
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of ZA201800787B publication Critical patent/ZA201800787B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA2018/00787A 2015-08-27 2018-02-06 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy ZA201800787B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ71151415 2015-08-27
PCT/NZ2016/050135 WO2017034420A1 (en) 2015-08-27 2016-08-25 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Publications (1)

Publication Number Publication Date
ZA201800787B true ZA201800787B (en) 2025-08-27

Family

ID=58100623

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/00787A ZA201800787B (en) 2015-08-27 2018-02-06 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Country Status (9)

Country Link
US (2) US11414428B2 (2)
EP (1) EP3350188B1 (2)
JP (2) JP7334041B2 (2)
KR (1) KR20180048798A (2)
CN (1) CN108349997B (2)
AU (2) AU2016312848A1 (2)
CA (1) CA2996681C (2)
WO (1) WO2017034420A1 (2)
ZA (1) ZA201800787B (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
CN108969522B (zh) 2017-06-05 2023-03-28 复旦大学 N-苄基色胺酮类衍生物作为色氨酸双加氧酶(tdo)抑制剂的用途
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
CN120004785A (zh) * 2018-07-03 2025-05-16 诺华制药股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
MX2023010371A (es) 2021-03-05 2024-02-12 Univ Basel Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.
JP2025507981A (ja) 2022-03-04 2025-03-21 アンティド セラピューティクス インターナショナル ソシエテ ア レスポンサビリテ リミティー トリプトファンジオキシゲナーゼ(ido1及びtdo)の二重阻害剤と療法におけるそれらの使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001255410A1 (en) 2000-04-14 2001-10-30 Corvas International, Inc. Substituted hydrazinyl heteroaromatic inhibitors of thrombin
CA2559105A1 (en) 2004-03-16 2005-09-29 Janssen Pharmaceutica N.V. Benzisoxazoles
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
DE102005018389A1 (de) 2005-04-20 2006-10-26 Sanofi-Aventis Deutschland Gmbh Azolderivate als Inhibitoren von Lipasen und Phospholipasen
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
CA2754934A1 (en) 2009-03-10 2010-09-16 Gruenenthal Gmbh Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
MX2012009377A (es) 2010-02-11 2012-09-12 Univ Vanderbilt Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
DK2595995T3 (en) 2010-07-22 2016-02-29 Basf Se Herbicidal isoxazolo [5,4-b] pyridines
EP2802212B1 (en) 2012-01-12 2015-12-30 Basf Se Herbicidal isoxazolo[5,4-b]pyridines
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
SG11201507395PA (en) 2013-03-14 2015-10-29 Curadev Pharma Private Ltd Inhibitors of the kynurenine pathway
US9931347B2 (en) 2013-12-03 2018-04-03 Iomet Pharma Ltd. Pharmaceutical compound
KR102746352B1 (ko) 2014-08-13 2024-12-24 오클랜드 유니서비시즈 리미티드 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
RU2619120C1 (ru) 2016-06-06 2017-05-12 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике

Also Published As

Publication number Publication date
HK1258665A1 (en) 2019-11-15
JP2022033753A (ja) 2022-03-02
CN108349997A (zh) 2018-07-31
EP3350188A1 (en) 2018-07-25
AU2016312848A1 (en) 2018-03-29
US20220411438A1 (en) 2022-12-29
CA2996681C (en) 2024-04-09
JP2018525430A (ja) 2018-09-06
KR20180048798A (ko) 2018-05-10
AU2021212003B2 (en) 2023-09-14
EP3350188A4 (en) 2019-04-03
US11414428B2 (en) 2022-08-16
EP3350188B1 (en) 2024-03-13
US20180244692A1 (en) 2018-08-30
CN108349997B (zh) 2025-06-10
AU2021212003A1 (en) 2021-08-26
CA2996681A1 (en) 2017-03-02
JP7334041B2 (ja) 2023-08-28
WO2017034420A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
ZA202405294B (en) Heterocyclic compounds as immunomodulators
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
ZA201800787B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
NZ784224A (en) Parp1 inhibitors
MY199705A (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12017502141A1 (en) Compounds and their methods of use
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX382562B (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub).
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
EA201591781A1 (ru) Химические соединения
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
MX2018008362A (es) Derivados de quinolin-2-ona.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2017013360A (es) Métodos para tratar el cáncer.
PH12017501880A1 (en) Methods for treating cancer
BR112015029216A2 (pt) tratamento de vasculopatia coroidal polipoidal
JOP20180038A1 (ar) مثبطات pd-1/pd-l1
EA201992045A1 (ru) Ингибиторы pd-1/pd-l1
EA201990556A1 (ru) Ингибиторы клеточных метаболических процессов